Sugi Predict

Sugi Predict / Compounds / SCHEMBL2320409

SCHEMBL2320409

SCHEMBL2320409

OB(O)c1ccc(N(Cc2ccccc2)Cc2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.58
▸ NR1H2 P55055 3/20 0.51
▸ NR1H3 Q13133 3/20 0.51
▸ TSHR P16473 3/20 0.50
▸ CA4 P22748 1/20 0.48
▸ CA6 P23280 1/20 0.48
▸ CA5A P35218 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ ENPP2 Q13822 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48
▸ CA5B Q9Y2D0 1/20 0.48
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ MGLL Q99685 1/20 0.47
▸ NR3C1 P04150 1/20 0.46
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ CNR2 P34972 2/20 0.46
▸ CYP2D6 P10635 2/20 0.42
▸ TAAR1 Q96RJ0 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5375915 0.84 CYP2C19 (0.53) CYP2C19NR1H2NR1H3TSHRMGLL
SCHEMBL2960872 0.83 CYP2C19 (0.78) CYP2C19NR1H2NR1H3TSHRMGLL
SCHEMBL29954351 0.82 TSHR (0.68) CYP2C19NR1H2NR1H3TSHRCA4
SCHEMBL29952570 0.81 NR1H2 (0.54) CYP2C19NR1H2NR1H3TSHRCA4
SCHEMBL2011193 0.81 CYP2C19 (0.69) CYP2C19NR1H2NR1H3TSHRNR3C1
SCHEMBL12663169 0.80 CA4 (0.52) CA4CA6CA5ACA7ENPP2
SCHEMBL3540071 0.80 NR3C1 (0.50) TSHRENPP2CA1CA2MGLL
SCHEMBL43183 0.79 TSHR (0.74) CYP2C19NR1H2NR1H3TSHRNR3C1
SCHEMBL2957378 0.78 CYP2C19 (0.64) CYP2C19NR1H2NR1H3TSHRNR3C1
SCHEMBL7154167 0.77 CYP2C19 (0.69) CYP2C19NR1H2NR1H3TSHRNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
EP-3414234-B1 BRUTON'S TYROSINE KINASE INHIBITORS ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) 2022-06-29 — — EP disclosed
EP-3414234-B1 BRUTON'S TYROSINE KINASE INHIBITORS ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) 2022-06-29 — — EP disclosed
US-10358446-B2 Bruton's tyrosine kinase inhibitors ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO., LTD. (CN) 2019-07-23 — — US disclosed
US-10358446-B2 Bruton's tyrosine kinase inhibitors ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO., LTD. (CN) 2019-07-23 — — US disclosed
EP-3414234-A1 BRUTON'S TYROSINE KINASE INHIBITORS Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. (CN) 2018-12-19 — — EP disclosed
US-20180222904-A1 BRUTON'S TYROSINE KINASE INHIBITORS SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2018-08-09 — — US disclosed
US-20180222904-A1 BRUTON'S TYROSINE KINASE INHIBITORS SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2018-08-09 — — US disclosed
WO-2017066014-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNNYLIFE PHARMA INC. (US) 2017-04-20 — — WO disclosed
WO-2017066014-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNNYLIFE PHARMA INC. (US) 2017-04-20 — — WO disclosed
WO-2010054764-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 — — WO disclosed
WO-2010054762-A1 AMINOALKYL-SUBSTITUTED COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 — — WO disclosed
WO-2010054764-A1 HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 — — WO disclosed
WO-2010054763-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 — — WO disclosed
US-7196219-B2 Preparation of Anilineboronic acids and derivatives thereof ARCHIMICA GMBH (DE) 2007-03-27 — — US disclosed
EP-1479686-B1 Process for the preparation of aniline boronic acids and derivatives thereof ARCHIMICA GMBH (DE) 2006-10-04 — — EP disclosed
US-20050065195-A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2005-03-24 — — US disclosed
US-20050038287-A1 Preparation of Anilineboronic acids and derivatives thereof CLARIANT GMBH 2005-02-17 — — US disclosed
EP-1479686-A1 Process for the preparation of aniline boronic acids and derivatives thereof Clariant GmbH (DE) 2004-11-24 — — EP disclosed
US-5800624-A LIPOPHILIC POLYMER, HYDROPHOBIC PLASTICIZER, QUATERNARY AMMONIUM OR PHOSPHONIUM CARRIER UNIVERSITY OF NOTRE DAME (US) 1998-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065195-A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors MAPK3, MAPK1, MAPKAPK3 CYP2C19 397/4885NR1H2 626/4885NR1H3 588/4885
US-20050038287-A1 Preparation of Anilineboronic acids and derivatives thereof C9, BLVRB, CBR3 CYP2C19 202/4885NR1H2 667/4885NR1H3 401/4885
US-20180222904-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK CYP2C19 676/4885NR1H2 3775/4885NR1H3 3894/4885
US-10358446-B2 Bruton's tyrosine kinase inhibitors BTK, ABL1, SYK CYP2C19 676/4885NR1H2 3775/4885NR1H3 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.